Two Cases of Autoimmune Thyroid Disorders after COVID Vaccination in Dialysis Patients

SARS-CoV-2 infection and vaccination have been associated with autoimmune thyroid dysfunctions. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and molecular mimicry have been referred to as potential causes. Such a case has not been reported in immunocompromised end-stage renal disease...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2022-10, Vol.23 (19), p.11492
Main Authors: Lioulios, Georgios, Tsouchnikas, Ioannis, Dimitriadis, Chrysostomos, Giamalis, Panagiotis, Pella, Eva, Christodoulou, Michalis, Stangou, Maria, Papagianni, Aikaterini
Format: Article
Language:English
Subjects:
Adjuvants
Adult
Aged
Antibodies
Antigens
Antihypertensives
Asymptomatic
BNT162b2
Case Report
Chemokines
Coronaviruses
COVID-19 - prevention & control
COVID-19 vaccines
COVID-19 Vaccines - adverse effects
End-stage renal disease
ESRD
Female
Graves Disease - chemically induced
Hashimoto Disease - chemically induced
Hemodialysis
Humans
Hypothyroidism
Infections
Inflammation
Kidney diseases
Laboratories
Ligands
Male
Mimicry
mRNA
mRNA Vaccines
Pathogens
Patients
Peritoneal dialysis
Population
Renal Dialysis - adverse effects
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Thyroid diseases
Thyroiditis
Vaccination
Vaccination - adverse effects
Vaccines, Synthetic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SARS-CoV-2 infection and vaccination have been associated with autoimmune thyroid dysfunctions. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and molecular mimicry have been referred to as potential causes. Such a case has not been reported in immunocompromised end-stage renal disease (ESRD) patients. Herein we present two dialysis patients with no previous history of thyroid disease who developed immune mediated thyroid disorders after BNT162b mRNA vaccine against SARS-CoV-2. The first patient is a 29-year-old man on hemodialysis diagnosed with Grave's disease four months post-vaccination and the second one is a 67-year-old female on peritoneal dialysis who developed Hashimoto's thyroiditis two months post-vaccination. Grave's disease is uncommon in dialysis patients, whereas Hashimoto's thyroiditis has a higher incidence in this population. Time proximity in both cases suggests potential causality. To our knowledge, this is the first report of de novo immune-mediated thyroid disorders in dialysis patients following vaccination against SARS-CoV-2.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms231911492